Cartesian's CAR-T works again when myasthenia gravis returns

Cartesian Therapeutics presented retreatment data for Descartes-08 at the AANEM annual meeting in Orlando on 29 September 2026. Descartes-08 is a CAR-T cell therapy for generalized myasthenia gravis, an autoimmune disease in which antibodies block the signal from nerve to muscle and cause weakness.

Most CAR-T therapies need chemotherapy beforehand to clear room for the new cells. According to the company, Descartes-08 does not, and it can be given as an outpatient. The question this data addresses is what happens when the disease comes back.

Five patients were retreated a median of 16.6 months after their first course, with the same six weekly infusions. Twelve months after retreatment, their MG-ADL score, a measure of daily function, had fallen by 6.6 points on average, and their MGC clinical score by 15 points. All five had clinically meaningful improvement, and four kept it on MG-ADL through month 12. No serious adverse events were reported during retreatment: no cytokine release syndrome, no immune effector cell-associated neurotoxicity syndrome, no cytopenias.

Five patients is a small group, and the figures come from the company. The Phase 3 AURORA trial is expected to report topline results in the first quarter of 2027.